MDS2

What MDS2 Is Used For

MDS2 is not a device security control in itself, it is a disclosure and comparison form. It gives buyers a structured way to ask vendors the same questions about authentication, encryption, logging, data handling, and incident response, so procurement, security, and clinical stakeholders can compare claims on a like-for-like basis.

That matters because medical technology often lives inside mixed clinical, IT, and vendor-managed environments. A completed form can reveal whether a product relies on weak defaults, unclear ownership, or controls that only exist in the buyer’s environment rather than in the product design.

What Information MDS2 Typically Captures

The form is usually organised around control domains rather than narrative prose. It asks whether the product supports or requires specific protections, and whether the vendor can describe how they are implemented, maintained, and supported across the product lifecycle.

Common topics include authentication methods, password and account handling, encryption in transit and at rest, audit logging, data retention, remote access, patching, backup, and incident response responsibilities. In other words, it turns a vendor security posture into a set of comparable control statements.

How MDS2 Supports Product Risk Assessment

MDS2 helps buyers move beyond sales claims and assess whether a product fits their risk tolerance, network architecture, and operational model. It is especially useful when a device or service processes sensitive clinical, operational, or patient-adjacent data, because security questions often affect deployment decisions, segmentation, support model, and acceptance criteria.

For that reason, many organisations pair the form with broader medical device guidance such as Medical Device Security Guide and, where applicable, regulatory interpretation such as EU MDR Cybersecurity and MDCG 2019-16 Guide.

The practical value is not just completeness, it is comparability. A good response shows where security is built into the product, where the customer must compensate with local controls, and where there may be uncertainty that needs follow-up before purchase or rollout.

How to Interpret MDS2 Responses

An MDS2 response should be treated as evidence, not assurance. A “yes” answer only matters if it is specific enough to be verified against documentation, architecture, or operational practice, and if the scope of the answer matches the product version, deployment model, and hosting arrangement being evaluated.

Security teams should look for gaps between stated features and actual operating conditions, especially where remote access, updates, telemetry, third-party support, or shared infrastructure change the control boundary. A vendor may describe a control correctly in principle while leaving material exposure in configuration, support processes, or incident handling.

That is why control statements should be cross-checked against authoritative security baselines and product documentation, including the vendor advisory, relevant standards, and, where needed, the device’s own safety and support materials.

Risk and Threat Considerations

MDS2 reduces procurement blind spots, but it can also create false confidence if buyers treat the form as proof of security rather than a disclosure instrument. The main risk is incomplete or overstated answers that hide weak defaults, unclear incident response ownership, or controls that depend on the purchaser’s environment rather than the product itself.

Failure mechanism: If the form is outdated, answered generically, or not reconciled with the actual deployment model, a buyer may approve a product that exposes sensitive systems to avoidable access, data handling, or support-channel risk.

Impact: The result can be preventable exposure of clinical or operational data, delayed containment during incidents, and a weaker security baseline across connected devices or services.

Practitioner Guidance

Why practitioners should care: MDS2 is most useful when procurement, security, biomedical engineering, and service owners treat it as a shared control-evidence document. That makes ownership clearer, especially when the vendor, integrator, and customer each control different parts of the risk picture.

What to watch for: Pay attention to vague answers, missing deployment context, and controls that only work under narrow assumptions. If the response does not clearly distinguish product capability from customer responsibility, it is not yet decision-grade.

Practitioner takeaway: Use MDS2 to drive follow-up questions, not to close the review. The best responses lead to verification, contract conditions, and deployment decisions, not just checkbox completion.

Related resources from NHI Mgmt Group

• What fails when MDS2 data never reaches enforcement policy?
• Why does MDS2 data matter for healthcare security governance?
• What are common mistakes with Manufacturer Disclosure Statement for Medical Device Security (MDS2)?
• What is a practical example of a Manufacturer Disclosure Statement for Medical Device Security (MDS2)?